eClinical Technology and Industy News

Affini-T Therapeutics & Metagenomi Announce Next-Generation Gene Editing Partnership to Advance Cell Therapies for Solid Tumor Patients

Excerpt from the Press Release:

BOSTON & SEATTLE & EMERYVILLE, Calif.–(BUSINESS WIRE)–Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, and Metagenomi, Inc., a genetic medicines company with a versatile portfolio of next-generation, wholly-owned gene editing tools, today announced a partnership to enable Affini-T’s next generation ex vivo T cell receptor (TCR) cell therapies for solid tumor patients using Metagenomi’s novel proprietary gene editing systems.

“We are delighted to announce our partnership with Metagenomi and to apply their next-generation gene editing systems to our cell therapies targeting oncogenic and viral driver genes, including KRAS and p53, to provide the greatest impact for patients across a variety of hard-to-treat solid tumor types,” said Jak Knowles, M.D., Co-founder, President and Chief Executive Officer, Affini-T Therapeutics. “By working with Metagenomi, we will gain access to powerful, novel gene editing tools to make precise and multiplex edits to immune cells, thereby optimizing the effector function of our cell-based therapeutics.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?